Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00672984 · ClinicalTrials.gov registry record · Phase 1

Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

A Phase 1 study of Healthy Volunteers, sponsored by Shire.

Completed
Registry status
Phase 1
Development phase
83
Enrollment target
1
Study location

NCT00672984 is a Phase 1 study of Healthy Volunteers that has completed, run by Shire. The registered enrollment target is 83 participants, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00672984, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Shire.

COMPLETED
Registry status
Phase 1
Development phase
83 participants
Enrollment target
1
Study location

Study Summary

To assess the effect of immediate-release guanfacine hydrochloride, administered at therapeutic and supratherapeutic doses, on QT/QTc in healthy normal males and females

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG moxifloxacin
  • DRUG immediate release guanfacine hydrochloride

Study Locations (1)

Washington

  • Charles River Clinical Services Northwest, Inc. - Tacoma

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2008-04-18
Est. Completion 2008-08-07
Phase Phase 1

Sponsor

Shire

245 total trials

What the Registry Record Tells You About NCT00672984

The ClinicalTrials.gov registry entry for NCT00672984 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 481-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (83% lower). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00672984 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00672984 about?

NCT00672984 is a clinical study titled "Guanfacine Immediate-release Electrocardiogram Results (QTc) Study". To assess the effect of immediate-release guanfacine hydrochloride, administered at therapeutic and supratherapeutic doses, on QT/QTc in healthy normal males and females

What is the current status of trial NCT00672984?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2008-04-18. Estimated completion is 2008-08-07.

What conditions does trial NCT00672984 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT00672984?

The interventions under investigation include: Placebo (DRUG), moxifloxacin (DRUG), immediate release guanfacine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00672984?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00672984 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.